Cystic Fibrosis: all 1,605 studies

Page 5 of 17. Open to participants first (196), then studies with results posted, then the rest; newest registration first within each.

• Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating MutationCompletedNCT01705145Phase 3Results posted
• Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic FibrosisTerminatedNCT01694069Phase 4Results posted
• Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR FunctionCompletedNCT01685801Phase 2Results posted
• Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic FibrosisCompletedNCT01684410Phase 2Results posted
• Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CFCompletedNCT01641822Phase 3Results posted
• Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant SuitabilityCompletedNCT01615484Not applicableResults posted
• Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating MutationCompletedNCT01614470Phase 3Results posted
• Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)CompletedNCT01614457Phase 3Results posted
• Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)CompletedNCT01594827Phase 2Results posted
• Cystic Fibrosis Related Bone Disease: the Role of CFTRCompletedNCT01549314Results posted
• Inhaled Vancomycin Tolerability, Safety and PharmacokineticsCompletedNCT01537666Phase 1Results posted
• Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) MutationCompletedNCT01531673Phase 2Results posted
• Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic FibrosisCompletedNCT01519661Phase 4Results posted
• Imaging Airway Liquid Absorption in Cystic FibrosisCompletedNCT01486199Not applicableResults posted
• Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) ChildrenCompletedNCT01429259Phase 4Results posted
• Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic FibrosisCompletedNCT01427712Results posted
• Effect of Glycine in Cystic FibrosisTerminatedNCT01417481Phase 2Results posted
• Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower AirwaysCompletedNCT01404234Phase 3Results posted
• Aztreonam Lysine for Pseudomonas Infection Eradication StudyCompletedNCT01375049Phase 2Results posted
• Inhaled Xylitol Versus Saline in Stable Subjects With Cystic FibrosisCompletedNCT01355796Phase 1/2Results posted
• Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)TerminatedNCT01349192Phase 2Results posted
• Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic InsufficiencyCompletedNCT01327703Phase 4Results posted
• Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) InfectionCompletedNCT01316276Phase 3Results posted
• Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa InfectionsCompletedNCT01315678Phase 3Results posted
• Effect of Sulforaphane in Broccoli Sprouts on Nrf2 ActivationCompletedNCT01315665Not applicableResults posted
• Detection of Pseudomonas Aeruginosa in the Airways of Patients With CFCompletedNCT01303068Not applicableResults posted
• Hypertonic Saline and Mucociliary Clearance in ChildrenCompletedNCT01293084Phase 2Results posted
• Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) PatientsCompletedNCT01270347Phase 3Results posted
• Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D MutationCompletedNCT01262352Phase 2Results posted
• Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR MutationCompletedNCT01225211Phase 2Results posted
• Absorptive Clearance After Inhaled Osmotics in Cystic FibrosisCompletedNCT01223183Phase 1Results posted
• Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary AspergillosisCompletedNCT01222273Not applicableResults posted
• MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic FibrosisCompletedNCT01180634Phase 3Results posted
• Tiotropium Bromide in Cystic FibrosisCompletedNCT01179347Phase 3Results posted
• Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D MutationCompletedNCT01161537Phase 2Results posted
• Extension Study of Ataluren (PTC124) in Cystic FibrosisCompletedNCT01140451Phase 3Results posted
• Effects of Sildenafil on CFTR-dependent Ion Transport ActivityCompletedNCT01132482Phase 2Results posted
• PR-018: An Open-Label, Safety Extension of Study PR-011CompletedNCT01131507Phase 4Results posted
• Rollover Study of VX-770 in Cystic Fibrosis SubjectsCompletedNCT01117012Phase 3Results posted
• Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) PatientsCompletedNCT01112059Not applicableResults posted
• Early Intervention in Cystic Fibrosis ExacerbationCompletedNCT01104402Not applicableResults posted
• A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of AgeCompletedNCT01100606Phase 4Results posted
• Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic FibrosisCompletedNCT01094704Phase 1Results posted
• A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis PatientsCompletedNCT01093521Phase 1Results posted
• Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 YearsCompletedNCT01082367Phase 3Results posted
• Second Open Label Extension to Bridging Study CTBM100C2303CompletedNCT01069705Phase 3Results posted
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species InfectionCompletedNCT01059565Phase 3Results posted
• Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic FibrosisCompletedNCT01031706Not applicableResults posted
• Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast CancerCompletedNCT00999921Phase 4Results posted
• Open Label Extension to Bridging Study CTBM100C2303CompletedNCT00982930Phase 3Results posted
• Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic InsufficiencyCompletedNCT00981214Phase 3Results posted
• Prevention of Cystic Fibrosis DiabetesTerminatedNCT00967798Phase 3Results posted
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR MutationTerminatedNCT00953706Phase 2Results posted
• Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung DiseaseCompletedNCT00934362Phase 2Results posted
• Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) SubjectsCompletedNCT00928135Phase 1/2Results posted
• A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus PlaceboCompletedNCT00918957Phase 3Results posted
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D MutationCompletedNCT00909727Phase 3Results posted
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D MutationCompletedNCT00909532Phase 3Results posted
• Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant PatientsCompletedNCT00908830Results posted
• 28 Day Repeat Dose in Cystic Fibrosis PatientsCompletedNCT00903201Phase 2Results posted
• A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®CompletedNCT00885365Phase 3Results posted
• Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)CompletedNCT00880100Phase 3Results posted
• Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene MutationCompletedNCT00865904Phase 2Results posted
• Hyperpolarized Noble Gas MR Imaging for Pulmonary DisordersTerminatedNCT00846573Not applicableResults posted
• FDG-PET Imaging in Young Cystic Fibrosis PatientsCompletedNCT00846053Not applicableResults posted
• NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis PatientsCompletedNCT00809094Phase 2Results posted
• Study of Ataluren (PTC124™) in Cystic FibrosisCompletedNCT00803205Phase 3Results posted
• Growth Hormone Therapy for Wasting in Cystic FibrosisTerminatedNCT00803179Phase 1Results posted
• Single Dose of pGM169/GL67A in CF PatientsCompletedNCT00789867Phase 1/2Results posted
• An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)TerminatedNCT00787917Phase 4Results posted
• Phase II Study of Digitoxin to Treat Cystic FibrosisCompletedNCT00782288Phase 2Results posted
• Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)CompletedNCT00777296Phase 1/2Results posted
• Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic FibrosisCompletedNCT00775528Phase 3Results posted
• Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic FibrosisCompletedNCT00763412Not applicableResults posted
• Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive AgentsCompletedNCT00758771Results posted
• A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic FibrosisCompletedNCT00757848Phase 2Results posted
• Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas AeruginosaCompletedNCT00757237Phase 3Results posted
• Tolerability of Hypertonic Saline in Infants With Cystic FibrosisCompletedNCT00753987Phase 1Results posted
• Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic InsufficiencyCompletedNCT00743483Phase 2Results posted
• Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic FibrosisCompletedNCT00737100Phase 2Results posted
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. AeruginosaCompletedNCT00712166Phase 3Results posted
• Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic FibrosisCompletedNCT00706004Not applicableResults posted
• Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)CompletedNCT00690820Phase 3Results posted
• Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different SettingsCompletedNCT00685035Phase 4Results posted
• A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic FibrosisTerminatedNCT00680316Phase 4Results posted
• The Natural History of Small Airways Physiology in Diseased and Healthy StatesCompletedNCT00677560Results posted
• Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) PatientsCompletedNCT00677365Phase 2Results posted
• A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic InsufficiencyCompletedNCT00662675Phase 3Results posted
• Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung DiseaseCompletedNCT00659529Phase 1/2Results posted
• Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic FibrosisCompletedNCT00645788Phase 2Results posted
• Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)TerminatedNCT00639626Phase 2/3Results posted
• Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas AeruginosaCompletedNCT00638365Phase 1/2Results posted
• Long Term Administration of Inhaled Mannitol in Cystic FibrosisCompletedNCT00630812Phase 3Results posted
• Self-dispersing Liquids as Aerosol Drug CarriersCompletedNCT00628134Not applicableResults posted
• Pharmacokinetics of Linezolid in Children With Cystic FibrosisCompletedNCT00625703Phase 2Results posted
• Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)TerminatedNCT00590538Phase 1/2Results posted
• Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic FibrosisCompletedNCT00570349Phase 1/2Results posted
• Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas AeruginosaCompletedNCT00558844Phase 1/2Results posted
• Absorptive Clearance in the Cystic Fibrosis AirwayCompletedNCT00541190Not applicableResults posted
• Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy VolunteersCompletedNCT00531882Not applicableResults posted

← Cystic Fibrosis overview